Free tool
Drug Trial Radar: Rare and genetic disease
Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
13
Recruiting, industry sponsors, Rare and genetic disease, Phase 3
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed102
13 trials
Showing 1 to 13, recently updated first.
- A Study to Learn How Well Lucerastat Works and How Safe it is in Untreated Adult Male Participants With Fabry DiseasePivotal-lookingRecruiting
Idorsia Pharmaceuticals Ltd.Industry
NCT07778667 · 16 participants (planned) · Start Dec 1, 2026 · Primary completion Feb 13, 2029
Drug: Lucerastat · For: Fabry Disease
Sites: Birmingham, Alabama; Oakland, California; Gainesville, Florida · 16 sites in all
- A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease (NPC)Pivotal-lookingRecruiting
Azafaros B.V.Industry
NCT07082725 · 72 participants (planned) · Start Jun 30, 2025 · Primary completion May 14, 2028
Drug: Nizubaglustat; Placebo · For: Niemann-Pick Type C Disease
Sites: Oakland, California; Minneapolis, Minnesota; Rochester, Minnesota · 34 sites in all
- A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease, GM1 Gangliosidosis or GM2 GangliosidosisPivotal-lookingRecruiting
Azafaros B.V.Industry
NCT07054515 · 147 participants (planned) · Start Jun 30, 2025 · Primary completion May 14, 2028
Drug: AZ-3102; Placebo · For: Niemann-Pick Type C Disease; GM1 Gangliosidosis; GM2 Gangliosidosis
Sites: Oakland, California; Minneapolis, Minnesota; Rochester, Minnesota · 39 sites in all
- A Study of Sepiapterin in Participants With Phenylketonuria (PKU)Pivotal-lookingRecruiting
PTC TherapeuticsIndustry
NCT06302348 · 56 participants (planned) · Start Mar 4, 2024 · Primary completion Feb 28, 2031
Drug: Sepiapterin · For: Phenylketonuria
Sites: Indianapolis, Indiana; Nedlands, Australia; North Adelaide, Australia · 14 sites in all
- A Study of Migalastat in Pediatric Subjects (2 to <12 Yrs) With Fabry Disease and Amenable GLA VariantsPivotal-lookingRecruiting
Amicus TherapeuticsIndustry
NCT06904261 · 8 participants (planned) · Start Jan 8, 2026 · Primary completion Dec 2027
Drug: Migalastat HCl 20 mg · For: Fabry Disease
Sites: Atlanta, Georgia; Minneapolis, Minnesota; Charlotte, North Carolina · 12 sites in all
- A Study of JNT-517 in Participants With Phenylketonuria (PKU)Pivotal-lookingRecruiting
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT06971731 · 120 participants (planned) · Start Oct 20, 2025 · Primary completion Mar 1, 2028
Drug: JNT-517; JNT-517 Matching Placebo · For: Phenylketonuria
Sites: Los Angeles, California; Gainesville, Florida; Tampa, Florida · 26 sites in all
- RAPA-501 Therapy for ALSPivotal-lookingRecruiting
Rapa Therapeutics LLCIndustry
NCT04220190 · 41 participants (planned) · Start Jan 2, 2025 · Primary completion Jul 1, 2027
Drug: RAPA-501 Autologous T stem cells · For: Amyotrophic Lateral Sclerosis
Sites: Boston, Massachusetts
- Phase I/II/III Gene Transfer Clinical Trial of scAAV9.U1a.hSGSHPivotal-lookingRecruiting
Ultragenyx Pharmaceutical IncIndustry
NCT02716246 · 36 participants (planned) · Start Apr 25, 2016 · Primary completion Mar 2029
Drug: UX111; Prophylactic Immunomodulatory (IM) Therapy and 2 more · For: MPS IIIA; Sanfilippo Syndrome; Sanfilippo A and 1 more
Sites: Columbus, Ohio; Pittsburgh, Pennsylvania; North Adelaide, Australia · 5 sites in all
- A Study to Learn About the Safety and Effects of the Study Drug PRX-102 in Children and Adolescents With Fabry DiseasePivotal-lookingRecruiting
Chiesi Farmaceutici S.p.A.Industry
NCT06328608 · 22 participants (planned) · Start Jul 29, 2025 · Primary completion Oct 2028
Drug: PRX-102 1 mg/kg every two weeks · For: Fabry Disease
Sites: Phoenix, Arizona; Atlanta, Georgia; Iowa City, Iowa · 12 sites in all
- A Long-Term Study of JNT-517 in Participants With PhenylketonuriaPivotal-lookingRecruiting
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT06628128 · 240 participants (planned) · Start Aug 11, 2025 · Primary completion Nov 1, 2027
Drug: JNT-517 · For: Phenylketonuria (PKU)
Sites: Gainesville, Florida; Tampa, Florida; Portland, Oregon · 12 sites in all
- A Pivotal Study of N-Acetyl-L-Leucine on Niemann-Pick Disease Type CPivotal-lookingRecruiting
IntraBio IncIndustry
NCT05163288 · 53 participants (planned) · Start Jun 30, 2022 · Primary completion Jun 12, 2030
Drug: N-Acetyl-L-Leucine · For: Niemann-Pick Disease, Type C
Sites: Rochester, Minnesota; Parkville, Australia; Prague, Czechia · 14 sites in all
- Study to Evaluate the Safety, PK, PD, and Efficacy of PRX-102 in Japanese Patients With Fabry DiseasePivotal-lookingRecruiting
Chiesi Farmaceutici S.p.A.Industry
NCT05710692 · 16 participants (planned) · Start Aug 1, 2023 · Primary completion Oct 2027
Drug: PRX-102 1 mg/kg every 2 weeks; PRX-102 2 mg/kg every 4 weeks · For: Fabry Disease
Sites: Chikushino-shi, Japan; Sendai, Japan; Nishihara, Japan · 10 sites in all
- A Study to Evaluate the Safety, Efficacy, PK, PD and Immunogenicity of Cipaglucosidase Alfa/Miglustat in IOPD Subjects Aged 0 to <18Pivotal-lookingRecruiting
Amicus TherapeuticsIndustry
NCT04808505 · 36 participants (planned) · Start Jul 18, 2023 · Primary completion Jul 2027
Drug: Cipaglucosidase alfa; Miglustat · For: Glycogen Storage Disease Type II Infantile Onset
Sites: Gainesville, Florida; Atlanta, Georgia; Durham, North Carolina · 14 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.